Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601684 | 0.85 | BRD4 (0.50) | BRD4NLRP3LMNAALDH1A1KDM4E | |
| SCHEMBL14263026 | 0.85 | BRD4 (0.50) | BRD4NLRP3LMNAALDH1A1KDM4E | |
| SCHEMBL18746451 | 0.85 | CTSA (0.40) | BRD4LMNAL3MBTL1CTSAALDH1A1 | |
| SCHEMBL19691717 | 0.84 | BRD4 (0.49) | BRD4LMNAALDH1A1KDM4ETP53 | |
| SCHEMBL2705086 | 0.82 | BRD4 (0.48) | BRD4LMNAL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL14697792 | 0.82 | BRD4 (0.48) | BRD4NLRP3LMNAALDH1A1KDM4E | |
| SCHEMBL16505732 | 0.81 | BRD4 (0.60) | BRD4LMNAL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL31453471 | 0.81 | BRD4 (0.60) | BRD4LMNAL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL15197855 | 0.81 | CTNNB1 (0.41) | LMNAL3MBTL1CTSAALDH1A1KDM4E | |
| SCHEMBL15868721 | 0.80 | CTNNB1 (0.46) | BRD4LMNAL3MBTL1CTSAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170290834-A1 | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-10-12 | — | — | US | disclosed |
| US-20170290834-A1 | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-10-12 | — | — | US | disclosed |
| US-9505758-B2 | Substituted 1,5-naphthyridines as endonuclease inhibitors | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-11-29 | — | — | US | disclosed |
| US-9505758-B2 | Substituted 1,5-naphthyridines as endonuclease inhibitors | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-11-29 | — | — | US | disclosed |
| EP-2945945-B1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-08-31 | — | — | EP | disclosed |
| EP-2945945-B1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-08-31 | — | — | EP | disclosed |
| US-20160039818-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-02-11 | — | — | US | disclosed |
| US-20160039818-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-02-11 | — | — | US | disclosed |
| US-9199987-B2 | Substituted naphthyridines for the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AU) | 2015-12-01 | — | — | US | disclosed |
| US-9199987-B2 | Substituted naphthyridines for the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AU) | 2015-12-01 | — | — | US | disclosed |
| US-8071605-B2 | Piperidine compounds for use in the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071605-B2 | Piperidine compounds for use in the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| WO-2010067123-A1 | 2- (PIPERIDIN-1-YL) -4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2008152418-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | WO | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | NISCH, PAK6, MYD88 | BRD4 2700/4885NLRP3 107/4885LMNA 2148/4885 |
| US-20170290834-A1 | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease | XDH, CYP27A1, ALAD | BRD4 3769/4885NLRP3 243/4885LMNA 393/4885 |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | NISCH, PIR, QDPR | BRD4 3457/4885NLRP3 221/4885LMNA 2265/4885 |
| US-20160039818-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | XDH, CYP27A1, ALAD | BRD4 3769/4885NLRP3 243/4885LMNA 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.